2007PubMedRequires access

[Therapeutic efficacy of a course administration of vardenafil--inhibitor of phosphodiesterase-5--in erectile dysfunction].

Iu G Aliaev, А З Винаров, Н Д Ахвледиани

Open publisher page 4 citations

Abstract

We studied a therapeutic effect of long-term and regular use of vardenafil which is an inhibitor of phosphodiesterase-5 (PDE-5) in patients with erectile dysfunction (n=32, mean age 35.7 +/- 6.8 years). They received the drug daily for 1 month in a dose 10 mg in the evening without direct sexual realization of the drug action. Before the treatment, upon 1 and 2 months of therapy the patients filled in questionnaire International Index of Erectile Function Scale (IIEFS) and underwent pharmacoechodopplerography of the penis. The erection scores by IIEFS after 1 month of vardenafil therapy increased from 17.8 +/- 4.5 to 23.7 +/- 5.3 (p < 0.01). On posttreatment day 30 this parameter went down to 21.9 +/- 5.6 scores (p < 0.01). However, this value was significantly better than the baseline (p < 0.01). The same dynamics was observed in objective indices of penile hemodynamics. Thus, routine daily intake of vardenafil produces a significant and persistent improvement of erectile function.

About this research paper

What this paper is about

We studied a therapeutic effect of long-term and regular use of vardenafil which is an inhibitor of phosphodiesterase-5 (PDE-5) in patients with erectile dysfunction (n=32, mean age 35.7 +/- 6.8 years). They received the drug daily for 1 month in a dose 10 mg in the evening without direct sexual realization of the drug action. Before the treatment, upon 1 and 2 months of therapy the patients filled in questionnaire International Index of Erectile Function Scale (IIEFS) and underwent pharmacoechodopplerography of the penis. The erection scores by IIEFS after 1 month of vardenafil therapy increased from 17.8 +/- 4.5 to 23.7 +/- 5.3 (p < 0.01). On posttreatment day 30 this parameter went down to 21.9 +/- 5.6 scores (p < 0.01). However, this value was significantly better than the baseline (p < 0.01). The same dynamics was observed in objective indices of penile hemodynamics. Thus, routine daily intake of vardenafil produces a significant and persistent improvement of erectile function.

Why it matters

OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

We studied a therapeutic effect of long-term and regular use of vardenafil which is an inhibitor of phosphodiesterase-5 (PDE-5) in patients with erectile dysfunction (n=32, mean age 35.7 +/- 6.8 years). They received the drug daily for 1 month in a dose 10 mg in the evening without direct sexual realization of the drug action. Before the treatment, upon 1 and 2 months of therapy the patients filled in questionnaire International Index of Erectile Function Scale (IIEFS) and underwent pharmacoechodopplerography of the penis. The erection scores by IIEFS after 1 month of vardenafil therapy increased from 17.8 +/- 4.5 to 23.7 +/- 5.3 (p < 0.01). On posttreatment day 30 this parameter went down to 21.9 +/- 5.6 scores (p < 0.01). However, this value was significantly better than the baseline (p < 0.01). The same dynamics was observed in objective indices of penile hemodynamics. Thus, routine daily intake of vardenafil produces a significant and persistent improvement of erectile function.

Key concepts: Vardenafil, Erectile dysfunction, Medicine, cGMP-specific phosphodiesterase type 5, Sildenafil, Phosphodiesterase inhibitor, Erectile function, Urology

Related papers

Back to paper searchBrowse research topicsOriginal source
[Therapeutic efficacy of a course administration of vardenafil--inhibitor of phosphodiesterase-5--in erectile dysfunction]. — Research Paper | ScholarLens